Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NWRD08 in Patients With HPV16 and/or HPV18 Positive Cervical HSIL
NCT05905354Phase 1Unknown
- Sponsor
- Newish Technology (Beijing) Co., Ltd.
- Start
- Mar 2022
- Primary completion
- Jun 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of NWRD08 in Squamous Intraepithelial Lesion (SIL) (4 arms), sponsored by Newish Technology (Beijing) Co., Ltd. Primary endpoint: HPV 16/18 E6E7 specific immune response at Week 36. Status: unknown.
02
Drugs
NWRD08
03
Conditions
Squamous Intraepithelial Lesion (SIL)
Beyond the preview
Go deeper on NCT05905354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05905354.